These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29992882)

  • 21. Cold atmospheric plasma inhibits the growth of Candida albicans by affecting ergosterol biosynthesis and suppresses the fungal virulence factors in vitro.
    Rahimi-Verki N; Shapoorzadeh A; Razzaghi-Abyaneh M; Atyabi SM; Shams-Ghahfarokhi M; Jahanshiri Z; Gholami-Shabani M
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():66-72. PubMed ID: 26739496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis.
    Lian CH; Liu WD
    Mycoses; 2007 Sep; 50(5):383-90. PubMed ID: 17714358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of phospholipase and proteinase activity in Candida albicans and C. dubliniensis.
    Fotedar R; Al-Hedaithy SS
    Mycoses; 2005 Jan; 48(1):62-7. PubMed ID: 15679669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Virulence factors of Candida albicans].
    Staniszewska M; Bondaryk M; Piłat J; Siennicka K; Magda U; Kurzatkowski W
    Przegl Epidemiol; 2012; 66(4):629-33. PubMed ID: 23484392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of Allyl Isothiocyanate and Its Synergy with Fluconazole against
    Raut JS; Bansode BS; Jadhav AK; Karuppayil SM
    J Microbiol Biotechnol; 2017 Apr; 27(4):685-693. PubMed ID: 28138121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of licorice compounds licochalcone A, glabridin and glycyrrhizic acid on growth and virulence properties of Candida albicans.
    Messier C; Grenier D
    Mycoses; 2011 Nov; 54(6):e801-6. PubMed ID: 21615543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenyl Pentyl Ketone and m-isobutyl Methoxy Benzoate Produced by
    Singh R; Ali M; Dubey AK
    Indian J Microbiol; 2023 Jun; 63(2):181-189. PubMed ID: 37325023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of secreted aspartyl proteinase activity in biofilms of Candida species by mycogenic silver nanoparticles.
    Hamid S; Zainab S; Faryal R; Ali N; Sharafat I
    Artif Cells Nanomed Biotechnol; 2018 May; 46(3):551-557. PubMed ID: 28541793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Candida albicans biofilm formation and yeast-hyphal transition by 4-hydroxycordoin.
    Messier C; Epifano F; Genovese S; Grenier D
    Phytomedicine; 2011 Mar; 18(5):380-3. PubMed ID: 21353508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative evaluation of tissue invasion by wild type, hyphal and SAP mutants of Candida albicans, and non-albicans Candida species in reconstituted human oral epithelium.
    Jayatilake JA; Samaranayake YH; Cheung LK; Samaranayake LP
    J Oral Pathol Med; 2006 Sep; 35(8):484-91. PubMed ID: 16918600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Citronellal-induced disruption of membrane homeostasis in Candida albicans and attenuation of its virulence attributes.
    Singh S; Fatima Z; Hameed S
    Rev Soc Bras Med Trop; 2016; 49(4):465-72. PubMed ID: 27598633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary Metabolites from Food-Derived Yeasts Inhibit Virulence of Candida albicans.
    Kunyeit L; Kurrey NK; Anu-Appaiah KA; Rao RP
    mBio; 2021 Aug; 12(4):e0189121. PubMed ID: 34399611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of pepstatin A on the virulence factors of Candida albicans strains isolated from vaginal environment of patients in three different clinical conditions.
    Consolaro ME; Gasparetto A; Svidzinski TI; Peralta RM
    Mycopathologia; 2006 Aug; 162(2):75-82. PubMed ID: 16897584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilising polyphenols for the clinical management of Candida albicans biofilms.
    Shahzad M; Sherry L; Rajendran R; Edwards CA; Combet E; Ramage G
    Int J Antimicrob Agents; 2014 Sep; 44(3):269-73. PubMed ID: 25104135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Candida albicans filamentation for antifungal drug development.
    Vila T; Romo JA; Pierce CG; McHardy SF; Saville SP; Lopez-Ribot JL
    Virulence; 2017 Feb; 8(2):150-158. PubMed ID: 27268130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of secretory aspartyl protease production in biofilms of Candida albicans exposed to sub-inhibitory concentrations of fluconazole.
    Mores AU; Souza RD; Cavalca L; de Paula e Carvalho A; Gursky LC; Rosa RT; Samaranayake LP; Rosa EA
    Mycoses; 2011 May; 54(3):195-201. PubMed ID: 19878458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virulence and pathogenicity of Candida albicans is enhanced in biofilms containing oral bacteria.
    Cavalcanti YW; Morse DJ; da Silva WJ; Del-Bel-Cury AA; Wei X; Wilson M; Milward P; Lewis M; Bradshaw D; Williams DW
    Biofouling; 2015; 31(1):27-38. PubMed ID: 25574582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis.
    Braga-Silva LA; Santos AL
    Curr Med Chem; 2011; 18(16):2401-19. PubMed ID: 21568917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application in Candida infection.
    Yordanov M; Dimitrova P; Patkar S; Saso L; Ivanovska N
    Can J Microbiol; 2008 Jun; 54(6):435-40. PubMed ID: 18535628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A non-polyenic antifungal produced by a Streptomyces yatensis strain isolated from Mellah Lake in El Kala, North-East of Algeria.
    Benouagueni S; Ranque S; Gacemi Kirane D
    J Mycol Med; 2015 Mar; 25(1):2-10. PubMed ID: 25458364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.